親環(huán)素A(CYPA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Cyclophilin A (CYPA)
PPIA; CyP-A; CYPH; Peptidylprolyl Isomerase A; Peptidyl-Prolyl Isomerase A; Peptidyl-prolyl cis-trans isomerase A; Cyclosporin A-binding protein
- 編號(hào)SEA979Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍1.56-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.64ng/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2722 ¥ 3888 ¥ 17496 ¥ 33048 ¥ 272160
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)親環(huán)素A(CYPA)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的親環(huán)素A(CYPA)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-101 | 95 |
| EDTA plasma(n=5) | 88-104 | 101 |
| heparin plasma(n=5) | 97-105 | 101 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的親環(huán)素A(CYPA)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中親環(huán)素A(CYPA)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-101% | 86-101% | 94-103% | 85-99% |
| EDTA plasma(n=5) | 97-105% | 94-102% | 97-104% | 95-102% |
| heparin plasma(n=5) | 90-104% | 91-99% | 85-99% | 84-98% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將親環(huán)素A(CYPA)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的親環(huán)素A(CYPA)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的親環(huán)素A(CYPA)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的親環(huán)素A(CYPA)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA979Mu01 | 親環(huán)素A(CYPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA979Mu02 | 親環(huán)素A(CYPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA979Mu02 | 親環(huán)素A(CYPA)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA979Mu01 | 親環(huán)素A(CYPA)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA979Mu01 | 抗親環(huán)素A(CYPA)多克隆抗體 | Flow cytometry. |
| LAA979Mu81 | 親環(huán)素A(CYPA)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAA979Mu71 | 親環(huán)素A(CYPA)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA979Mu21 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA979Mu22 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC |
| HEA979Mu | 親環(huán)素A(CYPA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEA979Mu | 親環(huán)素A(CYPA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA979Mu | 親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| PSA979Mu01 | 親環(huán)素A(CYPA)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA979Mu01 | 親環(huán)素A(CYPA)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Atherosclerosis | EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation [PubMed: 19758589] |
| Biomarkers | Cyclophilin-A: a novel biomarker for untreated male essential hypertension [Pubmed: 24164594] |
| Cardiovascular Diabetology | Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease [Pubmed:24502618] |
| International Journal of Biological Sciences | Decrease in Plasma Cyclophilin A Concentration at 1 Month after Myocardial Infarction Predicts Better Left Ventricular Performance and Synchronicity at 6 Months: A Pilot Study in Patients with ST Elevation Myocardial Infarction [Pubmed:25552928] |
| Medicine | Cyclophilin A in Ruptured Intracranial Aneurysm [PubMed: 26426668] |
| Mol Cell Biochem | PPIA rs6850: A> G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery disease [PubMed: 26702934] |
| Medicine (Baltimore) | Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy: A Cross-Sectional Analysis of Diabetes Mellitus [PubMed: 26496315] |
| International Journal of Cardiology | Cyclophilin?A?modulates?bone?marrow-derived?CD117(+)?cells?and?enhances?ischemia-induced?angiogenesisvia?the?SDF-1/CXCR4?axis. [Pubmed:27057951] |
| Clinica?Chimica?Acta | Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor [pubmed:27823952] |
| Cardiovascular?Diabetology | Cyclophilin?A?enhances?macrophage?differentiation?and?lipid?uptake?in?high?glucose?conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus. [pubmed:27809851] |
| Clinical?Science | Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity [Pubmed:29382697] |
| Journal of Molecular Histology | Cyclophilin a increases CD68 cell infiltration in rat experimental periodontitis [Pubmed:29318411] |
| Free?Radical?Research | Cyclophilin A and CD147 associate with progression of diabetic nephropathy [Pubmed: 30572748] |
| The Kaohsiung Journal of Medical Sciences | Association of cyclophilin A level and pulse pressure in predicting recurrence of cerebral infarction [Pubmed: 31670477] |
| Cells. | Cyclophilin A/EMMPRIN Axis Is Involved in Pro-Fibrotic Processes Associated with Thoracic Aortic Aneurysm of Marfan Syndrome Patients [Pubmed: 31936351] |
| JAMA Neurology | APPENDIX A: Relationship between cyclophilin A levels and matrix metalloproteinase-9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers?… [Pubmed: 24030206] |
| Menoufia Medical Journal | Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy [] |
| Toxins | Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy [34437430] |
| Cell Death & Disease | Proteomic analysis reveals USP7 as a novel regulator of palmitic acid-induced hepatocellular carcinoma cell death [Pubmed:35732625] |
